Abstract
CTLA-4 is a negative regulator of the proliferation and the effector function of T-cells. Therefore, it might be important to determine its expression on tumor cells and T-lymphocytes from cancer patients, to investigate its role in initiating and maintaining the neoplastic pathogenesis. CTLA-4 expression was detected in breast tissue by immunohistochemical staining and RT-PCR in 60 patients with breast cancer and 30 normal controls. The levels of CTLA-4 on T lymphocytes in 33 of the patients and 27 of the control group were determined by flow cytometry. Isolated peripheral blood mononuclear cells (PBMCs) were stimulated with phytohaemagglutinin (PHA). Stimulation index and IL-2 level in the cell culture supernatant were measured by MTT assay and ELISA method, respectively. Patients showed strong expression of CTLA-4 in the tumor cells of all specimens at both the protein and mRNA level, but only weakly positive or negative expression in normal breast tissue. Patients with higher mRNA level of CTLA-4 had obvious axillary lymph nodes metastases and higher clinical stage. Spontaneous expression of CD3+CTLA-4+ on PBMCs of tumor patients was also significantly higher than that of the controls. Moreover, PBMCs derived from patients with high expression of CD3+CTLA-4+ T-cells showed poor responsiveness to PHA stimulation and lower IL-2 production. Therefore, abnormal expression and dysregulation of CTLA-4 could partly explain the mechanism of evasion of anti-tumor immune responses in breast cancer patients and therefore highlight its importance in the development and progression of breast cancer.
Keywords: Breast cancer, CTLA-4, CD152, PBMC, flow cytometry, dysregulation, stimulation index, IL-2.
Current Cancer Drug Targets
Title:New Insights of CTLA-4 into Its Biological Function in Breast Cancer
Volume: 10 Issue: 7
Author(s): H. Mao, L. Zhang, Y. Yang, W. Zuo, Y. Bi, W. Gao, B. Deng, J. Sun, Q. Shao and X. Qu
Affiliation:
Keywords: Breast cancer, CTLA-4, CD152, PBMC, flow cytometry, dysregulation, stimulation index, IL-2.
Abstract: CTLA-4 is a negative regulator of the proliferation and the effector function of T-cells. Therefore, it might be important to determine its expression on tumor cells and T-lymphocytes from cancer patients, to investigate its role in initiating and maintaining the neoplastic pathogenesis. CTLA-4 expression was detected in breast tissue by immunohistochemical staining and RT-PCR in 60 patients with breast cancer and 30 normal controls. The levels of CTLA-4 on T lymphocytes in 33 of the patients and 27 of the control group were determined by flow cytometry. Isolated peripheral blood mononuclear cells (PBMCs) were stimulated with phytohaemagglutinin (PHA). Stimulation index and IL-2 level in the cell culture supernatant were measured by MTT assay and ELISA method, respectively. Patients showed strong expression of CTLA-4 in the tumor cells of all specimens at both the protein and mRNA level, but only weakly positive or negative expression in normal breast tissue. Patients with higher mRNA level of CTLA-4 had obvious axillary lymph nodes metastases and higher clinical stage. Spontaneous expression of CD3+CTLA-4+ on PBMCs of tumor patients was also significantly higher than that of the controls. Moreover, PBMCs derived from patients with high expression of CD3+CTLA-4+ T-cells showed poor responsiveness to PHA stimulation and lower IL-2 production. Therefore, abnormal expression and dysregulation of CTLA-4 could partly explain the mechanism of evasion of anti-tumor immune responses in breast cancer patients and therefore highlight its importance in the development and progression of breast cancer.
Export Options
About this article
Cite this article as:
Mao H., Zhang L., Yang Y., Zuo W., Bi Y., Gao W., Deng B., Sun J., Shao Q. and Qu X., New Insights of CTLA-4 into Its Biological Function in Breast Cancer, Current Cancer Drug Targets 2010; 10 (7) . https://dx.doi.org/10.2174/156800910793605811
DOI https://dx.doi.org/10.2174/156800910793605811 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The NK-1 Receptor is Involved in the Antitumoural Action of L-733,060 and in the Mitogenic Action of Substance P on Human Pancreatic Cancer Cell Lines
Letters in Drug Design & Discovery Application of Microdialysis in Clinical Pharmacology
Current Clinical Pharmacology Medicinal Chemistry Approaches of Controlling Gastrointestinal Side Effects of Non-Steroidal Anti-Inflammatory Drugs. Endogenous Protective Mechanisms and Drug Design
Medicinal Chemistry Review of Medicinal Plants Common to Traditional Chinese and Indian Medicines with Relevance to Non-Communicable Diseases
Current Traditional Medicine HSF1, A Versatile Factor in Tumorogenesis
Current Molecular Medicine Editorial: The Real Impact of Target Therapy in Cancer Patients: Between Hope and Reality
Current Cancer Drug Targets Chromogranin A in Tumors: More Than a Marker for Diagnosis and Prognosis
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Tumor Immune Escape Mechanisms that Operate During Metastasis
Current Pharmaceutical Biotechnology The Implication of Platelet Activating Factor in Cancer Growth and Metastasis: Potent Beneficial Role of PAF-Inhibitors and Antioxidants
Infectious Disorders - Drug Targets Neuroprotective Effects of Non-Classical Estrogen-Like Signaling Activators: from Mechanism to Potential Implications
CNS & Neurological Disorders - Drug Targets Translational Research of Optical Molecular Imaging for Personalized Medicine
Current Molecular Medicine Part II: Targeted Particles for Imaging of Anticancer Immune Responses
Current Drug Delivery Current Trends in the Application of Nanoparticles in Drug Delivery
Current Medicinal Chemistry Cardiovascular Effects of Neuregulin-1/ErbB Signaling: Role in Vascular Signaling and Angiogenesis
Current Pharmaceutical Design Investigating ABCB1-Mediated Drug-Drug Interactions: Considerations for In vitro and In vivo Assay Design
Current Drug Metabolism Cytotoxic and Antibiotic Potential of Secondary Metabolites from the Lichen <i>Umbilicaria muhlenbergii</i>
Current Pharmaceutical Biotechnology Therapeutic Peptide Mimetics Looking for a Turn to Block Aberrant Players of Malignancy
Current Cancer Therapy Reviews Antibody-Based Therapies in Systemic Lupus Erythematosus
Mini-Reviews in Medicinal Chemistry Selective Gene Amplification for High-Throughput Sequencing
Recent Patents on DNA & Gene Sequences Regulation of Hypoxia-inducible Factor-1α and Vascular Endothelial Growth Factor Signaling by Plant Flavonoids
Mini-Reviews in Medicinal Chemistry